Table 3 All-cause adverse events

From: Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

 

Part A

Part B

Total

Number of patients (%)

Saracatinib with C+P q3w ( N =24)

Saracatinib with C q3w ( N =21)

Saracatinib with P q3w ( N =27)

Saracatinib with P q1w ( N =24)

Saracatinib with C+P q3w ( N =20)

All patients ( N =116)

AEs occurring in 15% of patients overall

 Nausea

10 (42)

16 (76)

10 (37)

15 (63)

16 (80)

67 (58)

 Fatigue

15 (63)

11 (52)

12 (44)

13 (54)

9 (45)

60 (52)

 Decreased appetite

12 (50)

7 (33)

10 (37)

10 (42)

8 (40)

47 (41)

 Diarrhoea

10 (42)

6 (29)

7 (26)

11 (46)

9 (45)

43 (37)

 Vomiting

8 (33)

9 (43)

7 (26)

8 (33)

9 (45)

41 (35)

 Alopecia

10 (42)

2 (10)

9 (33)

6 (25)

13 (65)

40 (34)

 Anaemia

10 (42)

7 (33)

4 (15)

7 (29)

11 (55)

39 (34)

 Constipation

8 (33)

5 (24)

8 (30)

7 (29)

8 (40)

36 (31)

 Pyrexia

8 (33)

7 (33)

5 (19)

4 (17)

9 (45)

33 (28)

 Neutropenia

9 (38)

0

0

5 (21)

12 (60)

26 (22)

 Rash

6 (25)

2 (10)

3 (11)

9 (38)

5 (25)

25 (22)

 Dysgeusia

6 (25)

1 (5)

4 (15)

4 (17)

6 (30)

21 (18)

 Abdominal pain

2 (8)

5 (24)

5 (19)

5 (21)

2 (10)

19 (16)

 Arthralgia

5 (21)

0

5 (19)

4 (17)

5 (25)

19 (16)

 Cough

4 (17)

0

3 (11)

10 (42)

1 (5)

18 (16)

 Lethargy

2 (8)

2 (10)

5 (19)

5 (21)

4 (20)

18 (16)

 Weight decreased

5 (21)

3 (14)

3 (11)

3 (13)

4 (20)

18 (16)

AEs of CTC grade 3 occurring in 5% of patients overall

 Neutropenia

8 (33)

0

0

4 (17)

10 (50)

22 (19)

 Fatigue

4 (17)

3 (14)

3 (11)

1 (4)

5 (25)

16 (14)

 Anaemia

3 (13)

2 (10)

3 (11)

2 (8)

2 (10)

12 (10)

 Hyponatraemia

3 (13)

5 (24)

0

0

1 (5)a

9 (8)

 Leucopenia

2 (8)

0

0

0

7 (35)

9 (8)

 Asthenia

1 (4)

2 (10)

3 (11)

0

2 (10)

8 (7)

 Dyspnoea

1 (4)

2 (10)

1 (4)

2 (8)

0

6 (5)

 Hypokalaemia

1 (4)

2 (10)

0

2 (8)

1 (5)

6 (5)

 Thrombocytopenia

0

3 (14)

0

0

3 (15)

6 (5)

  1. Abbreviations: C=carboplatin; P=paclitaxel.
  2. aIn Part B, sodium 135 mmol l−1 at enrolment was an exclusion criterion.